Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
10.17
+0.19 (1.90%)
At close: Apr 2, 2026, 4:00 PM EDT
10.20
+0.03 (0.29%)
After-hours: Apr 2, 2026, 7:36 PM EDT
CRBP Employees
Corbus Pharmaceuticals Holdings had 36 employees as of December 31, 2025. The number of employees increased by 8 or 28.57% compared to the previous year.
Employees
36
Change (1Y)
8
Growth (1Y)
28.57%
Revenue / Employee
n/a
Profits / Employee
-$2,181,583
Market Cap
180.38M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 36 | 8 | 28.57% |
| Dec 31, 2024 | 28 | 9 | 47.37% |
| Dec 31, 2023 | 19 | -14 | -42.42% |
| Dec 31, 2022 | 33 | -8 | -19.51% |
| Dec 31, 2021 | 41 | -35 | -46.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| ProQR Therapeutics | 187 |
| Zentalis Pharmaceuticals | 166 |
| Adagene | 138 |
| Caribou Biosciences | 97 |
| Milestone Pharmaceuticals | 38 |
| Achieve Life Sciences | 25 |
| Unicycive Therapeutics | 23 |
CRBP News
- 27 days ago - Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 7 weeks ago - Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference - GlobeNewsWire
- 2 months ago - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 3 months ago - Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data Transcript - Seeking Alpha
- 4 months ago - Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss - GlobeNewsWire
- 4 months ago - Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 - GlobeNewsWire
- 5 months ago - Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire